Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study.
Cancer Metab
; 11(1): 6, 2023 May 18.
Article
in En
| MEDLINE
| ID: mdl-37202813
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
Language:
En
Journal:
Cancer Metab
Year:
2023
Type:
Article
Affiliation country:
United States